Women’s health biotech Gameto has closed a $44 million Series C funding round, enabling the company to complete the ongoing phase 3 trial for its lead cell therapy program, Fertilo, and file for regulatory approvals globally.
Fertilo uses engineered ovarian support cells (OSCs) derived from induced pluripotent stem cells (iPSCs) to mature eggs outside the body, reducing the standard ovarian stimulation protocol from two weeks of daily hormone injections to 2-3 days. Beyond its first-in-class status for infertility, Fertilo is also the first iPSC-derived therapy to reach late-stage clinical development in the U.S.
Fertilo is already cleared to commercialize in ex-U.S. jurisdictions and is currently used in clinics in Peru, Mexico and Australia, with additional clearances in Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay.
The recent financing round was led by Overwater Ventures, with participation from Insight Partners, RA Capital, Two Sigma Ventures, BOLD Capital Partners, Future Ventures, Ingeborg Investments, Arcadia Investment Partners, PAGS Group, Pontiva Healthcare Partners, Portfolia, and additional investors. Gameto has now raised a total of $127 million, positioning it among the largest funded companies in the reproductive biotech sector.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!